REAL WORLD FACTOR DISPENSATION AND EXPENDITURES IN US PATIENTS WITH HEMOPHILIA B: STANDARD HALF-LIFE VS. EXTENDED HALF-LIFE FACTOR IX REPLACEMENT PRODUCTS

被引：0
|
作者：
Chhabra, A. [1 ]
Spurden, D. [2 ]
Tortella, B. J. [3 ]
Fogarty, P. F. [3 ]
Pleil, A. [4 ]
Rubinstein, E. [1 ]
Alvir, J. [1 ]
机构：
[1] Pfizer Inc, New York, NY USA
[2] Pfizer Ltd, Surrey, England
[3] Pfizer Inc, Collegeville, PA USA
[4] Pfizer Inc, San Diego, CA USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.849
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY35
引用
收藏
页码：S111 / S111
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products
    Megias-Vericat, J. E.
    Bonanad Boix, S.
    Berrueco Moreno, R.
    Mingot-Castellano, M. E.
    Rodriguez Lopez, M.
    Canaro Hirnyk, M.
    Mateo Arranz, J.
    Calvo Villas, J. M.
    Haya Guaita, S.
    Mesegue Meda, M.
    Lopez Jaime, F.
    Albo-Lopez, C.
    Palomero-Massanet, A.
    Vilalta Seto, N.
    Larrode Lecinena, I
    Cid Haro, A. R.
    Poveda Andres, J. L.
    THROMBOSIS RESEARCH, 2022, 216 : 35 - 42
  • [42] In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients
    Preijers, T.
    van Spengler, M. W. F.
    Meijer, K.
    Fijnvandraat, K.
    Fischer, K.
    Leebeek, F. W. G.
    Cnossen, M. H.
    Mathot, R. A. A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (02) : 237 - 249
  • [43] In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients
    T. Preijers
    M. W. F. van Spengler
    K. Meijer
    K. Fijnvandraat
    K. Fischer
    F. W. G. Leebeek
    M. H. Cnossen
    R. A. A. Mathôt
    European Journal of Clinical Pharmacology, 2022, 78 : 237 - 249
  • [44] TAWAM HOSPITAL, AL AIN, UAE EXPERIENCE WITH SWITCHING FROM STANDARD HALF-LIFE RECOMBINANT COAGULATION FACTOR IX TO EXTEND HALF-LIFE RECOMBINANT COAGULATION FACTOR IX, FC FUSION PROTEIN IN PATIENTS WITH SEVERE HEMOPHILIA B
    Khanani, M. F.
    Osman, H.
    Rayyan, M. Z.
    Al Habaybia, K.
    Alreyami, L. A. E. M.
    Abd El Fattah, M.
    HAEMOPHILIA, 2023, 29 : 86 - 87
  • [45] PHARMACOKINETIC AND COST CONSIDERATIONS FOR TRANSITION TO EXTENDED HALF-LIFE (EHL) FACTOR VIII AND IX PRODUCTS
    Croteau, Stacy
    Neufeld, Ellis
    PEDIATRIC BLOOD & CANCER, 2015, 62 : 46 - 46
  • [46] The FIX C assessment of extended half-life recombinant factor IX products in clinical practice
    Bowyer, A.
    Sampson, B.
    Shepherd, F.
    Jones, R.
    Kitchen, S.
    Makris, M.
    HAEMOPHILIA, 2018, 24 : 56 - 56
  • [47] Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
    Teitel, Jerome
    Sholzberg, Michelle
    Iorio, Alfonso
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2021, 5 (02) : 349 - 355
  • [48] Pharmacokinetic and Cost Considerations for Transition to Extended Half-life (EHL) Factor VIII and IX Products
    Croteau, S.
    Neufeld, E.
    HAEMOPHILIA, 2015, 21 (03) : E262 - E262
  • [49] Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy : an update
    Aiello, Andrea
    Mancuso, Maria E.
    Leone, Serena
    Rossi, Letizia
    Cioni, Lorenzo
    Teruzzi, Cristina
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2022, 9 : 9 - 13
  • [50] Hemostatic Management in an Infant With Neuroblastoma and Severe Hemophilia B With Extended Half-life Recombinant Factor IX Fusion Protein
    Cuntz, Franziska
    Deubzer, Hedwig E.
    Schulte, Johannes H.
    Nimtz-Talaska, Antje
    Eggert, Angelika
    Holzhauer, Susanne
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2022, 44 (01) : E246 - E249
12345